A Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With NSCLC

NCT05756972 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

64

Enrollment

INDUSTRY

Sponsor class

Conditions

NSCLC

Interventions

DRUG: PM8002
DRUG: Carboplatin
DRUG: Pemetrexed

Sponsor

Biotheus Inc.